

**Glucocorticoids Induced End Organs Damage
in Patients with Systemic Lupus
Erythematosus**

Thesis

Submitted for Partial Fulfillment of the Master Degree
of Rheumatology

By

Mohammed Afify Abd-El-Atty

M.B.B.Ch

Supervised By

Prof. Dr. Eman Ahmed Hafez

Professor of Internal Medicine and Rheumatology
Faculty of Medicine - Ain Shams University

Dr. Noha Hussien Shedid

Assistant Professor of Internal Medicine and Rheumatology
Faculty of Medicine - Ain Shams University

Dr. Dalia AbdelHamid ElSherbiny

Lecturer of Internal Medicine and Rheumatology
Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University
2017**



Acknowledgement

First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

I would like to express my deep appreciation to my dear professor **Prof. Dr. Eman Ahmed Hafez**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind help, valuable support, I am deeply affected by her noble.

Moreover I would like to express my sincere and deepest gratitude to **Dr. Noha Hussien Sheded**, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for her supervision, help and valuable support and guidance, I am deeply affected by her character, perfection, care and consideration.

I wish to thank **Dr. Dalia AbdelHamid ELSherbiny**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her gracious supervision, valuable guidance, generous help, support and continuous encouragement through the whole research.

Many thanks to my family for their great support to complete this work.

I convey my thanks to anyone who helped me to complete this work.



Mohammed Afify Abd-El-Atty

Table of Contents

| | Page |
|--|------|
| - Acknowledgment | -- |
| - List of Abbreviations | i |
| - List of Tables | v |
| - List of Figures | xi |
| - Introduction | 1 |
| - Aim of the Work | 3 |
| - Review of Literature | 4 |
| • Chapter 1: Systemic Lupus Erythematosus ... | 4 |
| • Chapter 2: Glucocorticoids (GCs) | 31 |
| • Chapter 3: Adverse Effects of Glucocorticoids and End Organ Damage in SLE | 45 |
| - Subjects and Methods | 67 |
| - Results | 74 |
| - Discussion | 136 |
| - Summary and Conclusion | 155 |
| - Recommendations..... | 158 |
| - References | 160 |
| - Arabic summary | -- |

List of abbreviations

| | |
|-----------------|--|
| 11 β -HSD | : 11 β hydroxyl-steroid dehydrogenase. |
| 2H-PP | : 2-hours post-prandial blood sugar. |
| ACD | : Anemia of chronic disease. |
| ACE | : Angiotensin-converting enzyme. |
| aCL | : Anticardiolipin antibodies. |
| ACR | : American College of Rheumatology. |
| ACTH | : Adrenocorticotrophic hormone. |
| ADP | : Adenosine di-phosphate. |
| AECA | : Anti-endothelial cell antibodies. |
| AI | : Activity index. |
| AIHA | : Autoimmune hemolytic anemia. |
| ALHS | : Acute lupus hemophagocytic syndrome. |
| ANA | : Antinuclear antibody. |
| ANOVA | : One-way analysis of variance. |
| Anti-dsDNA | : Anti-double stranded DNA antibody. |
| Anti-NR2 | : Anti- N-methyl-D-aspartate glutamate receptor. |
| Anti-Sm | : Anti smith antibody. |
| AP-1 | : Activator protein 1. |
| aPL | : Anti-phospholipids antibodies. |
| APLAS | : Antiphospholipid-antibody syndrome. |
| aPTT | : Activated partial thromboplastin time. |
| ARBs | : Angiotensin II receptor blockers. |
| ATP | : Adenosine tri-phosphate. |
| AVN | : Avascular necrosis. |
| BlyS | : B-lymphocyte stimulator. |
| BMD | : Bone mineral density. |
| C | : Complement. |
| CAD | : Coronary artery disease. |
| CBC | : Complete blood count. |
| Cbfa1 | : Core-binding factor a1. |
| CHB | : Congenital heart block. |
| CI | : Chronicity index. |
| CK | : Creatine kinase. |

List of abbreviations (Cont.)

| | |
|-------|---|
| CLE | : Cutaneous lupus erythematosus. |
| CNS | : Central nervous system. |
| COX | : Cyclo-oxygenase enzyme. |
| CSs | : Corticosteroids. |
| CT | : Computed tomography. |
| CTDs | : Connective tissue diseases. |
| CVS | : Cardio-vascular system. |
| Cyc | : Cyclophosphamide. |
| CYP | : Cytochrome P isoenzymes. |
| DAH | : Diffuse alveolar hemorrhage. |
| DBD | : DNA-binding domain. |
| DEXA | : Dual energy X-ray absorptiometry. |
| DLE | : Discoid lupus. |
| DM | : Diabetes mellitus. |
| DMARD | : Disease modifying anti-rheumatic drugs. |
| DNA | : Deoxy-ribo nucleic acid. |
| EBV | : Epstein Barr virus. |
| ELISA | : Enzyme-linked immunosorbent assay. |
| EMG | : Electro-myogram. |
| ESR | : Erythrocyte sedimentation rate. |
| EULAR | : European League Against Rheumatism. |
| FBS | : Fasting blood sugar. |
| FM | : Fibromyalgia. |
| FN | : Femoral neck. |
| GCs | : Glucocorticoids. |
| GH | : Growth hormone. |
| GIO | : Glucocorticoid induced osteoporosis. |
| GLUT | : Glucose transporter. |
| GnRH | : Gonadotropin-releasing hormone. |
| GR | : Glucocorticoid receptor. |
| GREs | : GC-response elements. |
| Hb | : Hemoglobin. |
| HbA1c | : Glycosylated hemoglobin. |
| HCQ | : Hydroxychloroquine. |

List of abbreviations (Cont.)

| | |
|----------------|--|
| HLA-DR | : Human leucocytic antigen. |
| HPA | : Hypothalamic–pituitary– adrenal axis. |
| HRT | : Hormone replacement therapy. |
| HS | : Haemophagocytic syndrome. |
| hs-CRP | : highly sensitive C - reactive protein. |
| Hsp | : Heat-shock proteins. |
| HTN | : Hypertension. |
| IDA | : Iron deficiency anemia. |
| IGF | : Insulin-like growth factor. |
| IL | : Interleukin. |
| IPO | : Intestinal pseudo-obstruction. |
| IQR | : Inter-quartile ratio. |
| ISN/RPS | : International Society of Nephrology/Renal Pathology Society. |
| ITP | : Immune thrombocytopenia. |
| IVIG | : Intravenous immunoglobulin. |
| JA | : Jaccoud's arthropathy. |
| kD | : kilo-Danton. |
| LAC | : Lupus anticoagulant. |
| LBD | : Ligand-binding domain. |
| LBMD | : Low bone mineral density. |
| LDH | : Lactate dehydrogenase. |
| LDL | : Low density lipoprotein. |
| LR | : Livedo reticularis. |
| LS | : Lumbar spine. |
| MAPK | : Mitogen-activated protein kinase. |
| MHC | : Major histocompatibility complex. |
| MMF | : Mycophenolate mofetil. |
| MRI | : Magnetic resonance imaging. |
| mRNA | : Messenger ribo-nucleic acid. |
| NF- κ B | : Nuclear factor κ B. |
| NIH | : National Institutes of Health. |
| NO | : Nitric oxide. |
| NPSLE | : Neuro-psychiatric systemic lupus erythematosus. |

List of abbreviations (Cont.)

| | |
|----------------|--|
| NSAIDS | : Non-steroidal anti-inflammatory drugs. |
| NTD | : Amino-terminal domain. |
| P-gp | : P-glycoprotein. |
| PH | : Pulmonary hypertension. |
| PI3K | : Phosphatidyl-inositol-3-kinase. |
| PKB/Akt | : Akt/Protein kinase B. |
| PLGE | : Protein-losing gastroenteropathy. |
| PPAR- γ | : Peroxisome proliferator activated receptor- γ . |
| PSC | : Posterior subcapsular cataract. |
| PTH | : Parathyroid hormone. |
| RA | : Rheumatoid arthritis. |
| RANKL | : Receptor activator of nuclear factor- κ B ligand. |
| RBC | : Red blood cells. |
| RNP | : Ribonucleoprotein. |
| ROC | : Receiver operating characteristic. |
| RP | : Raynaud's phenomenon. |
| SD | : Standard deviation. |
| SEGRA | : Selective GCs receptor agonists. |
| SIDM | : Steroid induced diabetes mellitus. |
| SLE | : Systemic lupus erythematosus. |
| SLEDAI | : SLE disease activity index. |
| SLICC | : Systemic Lupus International Collaborating Clinics. |
| SLS | : Shrinking lung syndrome. |
| STATs | : Signal transducers and activators of transcription. |
| TCR | : T cell receptor. |
| TLC | : Total leucocytic count. |
| TNF | : Tumor necrosis factor. |
| TPOR | : Anti-thrombopoietin receptor. |
| TREGs | : Regulatory T-cells. |
| VEGF | : Vascular endothelial growth factors. |
| WBC | : White blood cell. |
| WHO | : World Health Organization. |

List of Tables

| Table No. | Title | Page No. |
|--------------------|---|----------|
| Table (1): | A modified version of Gilliam's classification of LE-specific skin manifestations | 9 |
| Table (2): | A modified version of Gilliam's classification of LE-non-specific skin disease. | 10 |
| Table (3): | The revised classification of glomerulonephritis in SLE..... | 17 |
| Table (4): | The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. | 20 |
| Table (5): | The 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE..... | 23 |
| Table (6): | The indications of immunosuppressive therapy in SLE..... | 29 |
| Table (7): | Pharmacodynamics of commonly used glucocorticoids.. | 34 |
| Table (8): | General measurements in the management of GIO..... | 50 |
| Table (9): | Grading of recommendations for pharmacological interventions approved for management of GIO | 51 |
| Table (10): | SLICC damage index | 70 |
| Table (11): | Demographic data among 50 SLE patients | 74 |
| Table (12): | Clinical data among 50 SLE patients | 75 |
| Table (13): | Clinical assessment among 50 SLE patients. | 75 |
| Table (14): | Treatments prescribed to the 50 SLE patients during the course of disease | 76 |
| Table (15): | Doses and durations of steroid treatment prescribed to the 50 SLE patients..... | 77 |

List of Tables (Cont.)

| Table No. | Title | Page No. |
|--------------------|--|----------|
| Table (16): | Laboratory data among 50 SLE patients. | 78 |
| Table (17): | Autoantibody profile among 50 SLE patients | 78 |
| Table (18): | BMD variables for the 50 SLE patients. | 78 |
| Table (19): | Frequency of osteoporosis and osteopenia in the 50 SLE patients..... | 79 |
| Table (20): | Frequency of steroid induced complications in the 50 SLE patients..... | 80 |
| Table (21): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS as regard some demographic and clinical data using ANOVA test..... | 81 |
| Table (22): | Comparison between patients with NBMD, osteopenia and osteoporosis at FN as regard some demographic and clinical data using ANOVA test..... | 82 |
| Table (23): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS and FN as regard the sex of 50 SLE patients using Chi square test..... | 83 |
| Table (24): | T Comparison between patients with NBMD, osteopenia and osteoporosis at LS as regard some laboratory investigations using ANOVA test | 84 |
| Table (25): | Comparison between patients with NBMD, osteopenia and osteoporosis at FN as regard some laboratory investigations using ANOVA test. | 85 |
| Table (26): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS and FN as regard medications received by patients using chi-square. | 86 |

List of Tables

| Table No. | Title | Page No. |
|--------------------|--|----------|
| Table (27): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS and FN as regard the cumulative, current dose and duration of steroid treatment using ANOVA test..... | 88 |
| Table (28): | Comparison between patients with AVN and patients without AVN as regard some demographic and clinical data using Student's t-test. | 89 |
| Table (29): | Comparison between patients with AVN and patients without AVN as regard the sex of 50 SLE patients using Chi square test. | 89 |
| Table (30): | Comparison between patients with AVN and patients without AVN as regard BMD variables using Student's t-test | 90 |
| Table (31): | Comparison between patients with AVN and patients without AVN as regard some laboratory investigations using Student's t-test. | 91 |
| Table (32): | Comparison between patients with AVN and patients without AVN as regard medications received by patients using chi-square..... | 92 |
| Table (33): | Comparison between patients with AVN and patients without AVN as regard the cumulative, current dose and duration of steroid treatment using Student's t-test..... | 93 |
| Table (34): | Comparison between patients with cataract and patients without cataract as regard some demographic and clinical data using Student's t-test. | 94 |
| Table (35): | Comparison between patients with cataract and patients without cataract as regard the sex of 50 SLE patients using Chi square test | 95 |

List of Tables

| Table. No. | Title | Page No. |
|--------------------|--|----------|
| Table (36): | Comparison between patients with cataract and patients without cataract as regard BMD variables using Student's t-test | 96 |
| Table (37): | Comparison between patients with cataract and patients without cataract as regard some laboratory investigations using Student's t-test | 97 |
| Table (38): | Comparison between patients with cataract and patients without cataract as regard medications received by patients using chi-square..... | 98 |
| Table (39): | Comparison between patients with cataract and patients without cataract as regard the cumulative, current dose and duration of steroid treatment using Student's t-test..... | 99 |
| Table (40): | Comparison between patients with DM and patients without DM as regard some demographic and clinical data using Student's t-test..... | 100 |
| Table (41): | Comparison between patients with DM and patients without DM as regard the sex of 50 SLE patients using Chi square test..... | 101 |
| Table (42): | Comparison between patients with DM and patients without DM as regard BMD variables using Student's t-test..... | 102 |
| Table (43): | Comparison between patients with DM and patients without DM as regard some laboratory investigations using Student's t-test..... | 102 |
| Table (44): | Comparison between patients with DM and patients without DM as regard medications received by patients using chi-square..... | 103 |

List of Tables

| Table No. | Title | Page No. |
|--------------------|--|----------|
| Table (45): | Comparison between patients with DM and patients without DM as regard the cumulative, current dose and duration of steroid treatment using Student's t-test..... | 104 |
| Table (46): | Comparison between steroid duration and frequency of complications among SLE patients using Chi square test..... | 105 |
| Table (47): | Comparison between cumulative steroid dose and frequency of complications among SLE patients using Chi square test..... | 106 |
| Table (48): | Correlation between BMD at LS and FN and some demographic and clinical data among 50 SLE patients using Pearson correlation test..... | 107 |
| Table (49): | Correlation between BMD at LS and FN and some laboratory investigations among 50 SLE patients using Pearson correlation test..... | 109 |
| Table (50): | Correlation between BMD at LS and FN and steroid dose and duration used among 50 SLE patients using Pearson correlation test..... | 109 |
| Table (51): | Correlation between T-score at LS and FN and some demographic and clinical data among 50 SLE patients using Pearson correlation test..... | 114 |
| Table (52): | Correlation between T-score at LS and FN and some laboratory investigations among 50 SLE patients using Pearson correlation test..... | 116 |
| Table (53): | Correlation between T-score at LS and FN and steroid dose and duration used among 50 SLE patients using Pearson correlation test..... | 116 |
| Table (54): | Correlation between Z-score at LS and FN and some demographic and clinical data among 50 SLE patients using Pearson correlation test..... | 121 |

List of Tables

| Table. No. | Title | Page No. |
|--------------------|--|-----------------|
| Table (55): | Correlation between Z-score at LS and FN and some laboratory investigations among 50 SLE patients using Pearson correlation test | 122 |
| Table (56): | Correlation between Z-score at LS and FN and steroid dose and duration used among 50 SLE patients using Pearson correlation test | 123 |
| Table (57): | Correlation study between steroid dose and duration, BMD LS, BMD FN, T-score, Z-score and each other among 50 SLE patients | 128 |
| Table (58): | Linear Regression model for the Factors affecting BMD (LS) | 129 |
| Table (59): | Linear Regression model for the Factors affecting BMD (FN)..... | 129 |
| Table (60): | Roc-curves of cumulative steroid levels to discriminate complicated from non-complicated cases | 130 |
| Table (61): | Roc-curves of current daily steroid levels to discriminate complicated from non-complicated cases | 133 |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|---|-----------------|
| Figure (1): | Basic steroid structure and configuration..... | 32 |
| Figure (2): | Genomic actions of GCs. | 39 |
| Figure (3): | Non-genomic actions of GCs..... | 40 |
| Figure (4): | Regulation of GC secretion by hypothalamic pituitary axis..... | 42 |
| Figure (5): | GC effects on immune system. | 43 |
| Figure (6): | Spectrum of GC therapy..... | 45 |
| Figure (7): | Direct and indirect effect of GC on bone leading to osteoporosis and fractures..... | 48 |
| Figure (8): | Pathophysiology of steroid induced avascular necrosis..... | 54 |
| Figure (9): | Steroid cataract formation..... | 60 |
| Figure (10): | Effect of GC on gluconeogenesis in adipose tissue and liver. | 63 |
| Figure (11): | Clinical assessment among 50 SLE patients..... | 76 |
| Figure (12): | Medications received by SLE patients..... | 77 |
| Figure (13): | Frequency of osteoporosis and osteopenia at LS and FN among SLE patients..... | 79 |
| Figure (14): | Frequency of steroid induced complications in the 50 SLE patients..... | 80 |
| Figure (15): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS and FN as regard the sex of 50 SLE patients..... | 83 |
| Figure (16): | Comparison between patients with NBMD, osteopenia and osteoporosis at LS as regard medications received by patients. | 87 |

List of Figures (Cont.)

| Fig. No. | Title | Page No. |
|----------------------------|---|----------|
| Figure (17): | Comparison between patients with NBMD, osteopenia and osteoporosis at FN as regard medications received by patients. | 87 |
| Figure (18): | Comparison between patients with AVN and patients without AVN as regards the sex of 50 SLE patients..... | 90 |
| Figure (19): | Comparison between patients with AVN and patients without AVN as regard medications received by patients | 93 |
| Figure (20): | Comparison between patients with cataract and patients without cataract as regards the sex of 50 SLE patients..... | 95 |
| Figure (21): | Comparison between patients with cataract and patients without cataract as regard medications received by patients. | 99 |
| Figure (22): | Comparison between patients with DM and patients without DM as regards the sex of 50 SLE patients. | 101 |
| Figure (23): | Comparison between patients with DM and patients without DM as regard medications received by patients..... | 104 |
| Figure (24): | Correlation between BMD LS and SLICC\ACR score..... | 108 |
| Figure (25): | Correlation between BMD FN and SLICC\ACR score:..... | 108 |
| Figures (26-27-28): | Correlation between BMD LS and steroid dose "cumulative, current and solumedrol". | 111 |
| Figures (29-30-31): | Correlation between BMD FN and steroid dose "cumulative, current and solumedrol" | 113 |